{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:55:18Z","timestamp":1760385318421},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,8,24]],"date-time":"2013-08-24T00:00:00Z","timestamp":1377302400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00520-013-1947-8","type":"journal-article","created":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T06:31:13Z","timestamp":1377239473000},"page":"7-14","source":"Crossref","is-referenced-by-count":17,"title":["Daptomycin use in neutropenic patients with documented gram-positive infections"],"prefix":"10.1007","volume":"22","author":[{"given":"Kenneth V. I.","family":"Rolston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Besece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Lamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A.","family":"McConnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,24]]},"reference":[{"key":"1947_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0002-9343(86)90510-3","volume":"81","author":"GP Bodey","year":"1986","unstructured":"Bodey GP (1986) Infection in cancer patients. A continuing association. Am J Med 81:11\u201326","journal-title":"Am J Med"},{"key":"1947_CR2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","volume":"64","author":"GP Bodey","year":"1966","unstructured":"Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328\u2013340","journal-title":"Ann Intern Med"},{"issue":"4","key":"1947_CR3","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):e56\u201393","journal-title":"Clin Infect Dis"},{"issue":"Suppl 4","key":"1947_CR4","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.1086\/427331","volume":"40","author":"KV Rolston","year":"2005","unstructured":"Rolston KV (2005) Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 40(Suppl 4):S246\u2013S252","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"1947_CR5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/491708","volume":"42","author":"RC Moellering Jr","year":"2006","unstructured":"Moellering RC Jr (2006) Vancomycin: a 50-year reassessment. Clin Infect Dis 42(Suppl 1):S3\u2013S4","journal-title":"Clin Infect Dis"},{"key":"1947_CR6","doi-asserted-by":"crossref","unstructured":"Cometta A, Kern WV, de Bock R, Paesmans M, Vandenbergh M, Crokaert F, Engelhard D, Marchetti O, Akan H, Skoutelis A, Korten V, Vandercam M, Gaya H, Padmos A, Klastersky J, Zinner S, Gauser MP, Calandra T, Viscoli C; International Antimicrobial Therapy Group of the European Organization for Research Treatment of Cancer (2003) Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 37(3):382\u201397","DOI":"10.1086\/376637"},{"key":"1947_CR7","doi-asserted-by":"crossref","unstructured":"Feld R (1999) Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis 29:503\u2013507","DOI":"10.1086\/598622"},{"key":"1947_CR8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-108-1-30","volume":"108","author":"M Rubin","year":"1988","unstructured":"Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA (1988) Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 108:30\u201335","journal-title":"Ann Intern Med"},{"issue":"3","key":"1947_CR9","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Rybak MJ, Talan DA, Chambers HF, Infectious Diseases Society of America (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52(3):e18\u201355","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1947_CR10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","volume":"49","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP (2009) Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49(3):325\u20137","journal-title":"Clin Infect Dis"},{"key":"1947_CR11","unstructured":"Kapadia M, Coyle E, Prince R, Rolston K (2005) Declining in vitro activity of vancomycin against Staphylococcus aureus isolates from cancer patients. Presented at: 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), December 16\u201319, 2005, Washington, DC. Abstract No. E-807"},{"issue":"17","key":"1947_CR12","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1634\/theoncologist.2012-0029","volume":"12","author":"SN Mahajan","year":"2012","unstructured":"Mahajan SN, Shah JN, Hachem R, Tverdek F, Adachi JA, Mulanovich V, Rolston KV, Raad II, Chemaly RF (2012) Characteristics and outcomes of methicillin-resistant Staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center. Oncologist 12(17):1329\u20131336","journal-title":"Oncologist"},{"key":"1947_CR13","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1086\/425009","volume":"39","author":"RW Finberg","year":"2004","unstructured":"Finberg RW, Moellering RC, Tally FP, Craig WA, Pankey GA, Dellinger EP, West MA, Joshi M, Linden PK, Rolston KV, Rotschafer JC, Rybak MJ (2004) The importance of bactericidal drugs: future directions in infectious disease. Clin Infect Dis 39:1314\u20131320","journal-title":"Clin Infect Dis"},{"key":"1947_CR14","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1128\/AAC.00738-06","volume":"51","author":"LI Mortin","year":"2007","unstructured":"Mortin LI, Li T, Van Praagh AD, Zhang S, Zhang XX, Alder JD (2007) Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother 51:1787\u20131794","journal-title":"Antimicrob Agents Chemother"},{"key":"1947_CR15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/dkh546","volume":"55","author":"JN Steenbergen","year":"2005","unstructured":"Steenbergen JN, Alder J, Thorne GM, Tally FP (2005) Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55:283\u2013288","journal-title":"J Antimicrob Chemother"},{"key":"1947_CR16","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1592\/phco.27.6.927","volume":"27","author":"GR Barber","year":"2007","unstructured":"Barber GR, Lauretta J, Saez R (2007) A febrile neutropenic patient with Enterococcus gallinarum sepsis treated with daptomycin and gentamicin. Pharmacotherapy 27:927\u2013932","journal-title":"Pharmacotherapy"},{"key":"1947_CR17","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijantimicag.2010.03.015","volume":"36","author":"AM Chaftari","year":"2010","unstructured":"Chaftari AM, Hachem R, Mulanovich V, Chemaly RF, Adachi J, Jacobson K, Jiang Y, Raad I (2010) Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents 36:182\u2013186","journal-title":"Int J Antimicrob Agents"},{"key":"1947_CR18","doi-asserted-by":"crossref","unstructured":"Hogan H, Raad I, Rolston K (2007) Daptomycin therapy for gram-positive infections in cancer patients. Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and 25th International Congress of Chemotherapy, March 31\u2013April 3, 2007, Munich, Germany. Abstract No. P-1666","DOI":"10.1016\/S0924-8579(07)71505-4"},{"key":"1947_CR19","unstructured":"Hogan HL, Adachi JA, Coyle EA, Rolston KVI (2007) Daptomycin therapy of gram-positive infections (GPI) in pediatric cancer patients. Presented at: 14th International Symposia on Infections in the Immunocompromised Host, June 2007, Thessaloniki, Greece"},{"key":"1947_CR20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jinf.2006.11.007","volume":"54","author":"DD Poutsiaka","year":"2007","unstructured":"Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR (2007) Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 54:567\u2013571","journal-title":"J Infect"},{"key":"1947_CR21","first-page":"249","volume":"8","author":"KV Rolston","year":"2010","unstructured":"Rolston KV, McConnell SA, Brown J, Lamp KC (2010) Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry. Clin Adv Hematol Oncol 8:249\u2013257","journal-title":"Clin Adv Hematol Oncol"},{"key":"1947_CR22","doi-asserted-by":"crossref","unstructured":"Rossetti JM, Thatikonda C, Shadduck RK, Sahovic E, Kaplan RB, Kennedy M, Lister J (2008) Daptomycin plus cefepime for moderate and high-risk febrile neutropenic patients with increased risk of gram-positive infection. Biol Blood Marrow Transplantation 14 (supplement):98","DOI":"10.1016\/j.bbmt.2007.12.274"},{"issue":"Suppl 1","key":"1947_CR23","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.amjmed.2007.07.008","volume":"120","author":"KV Rolston","year":"2007","unstructured":"Rolston KV, Segreti J, Lamp KC, Friedrich LV (2007) Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med 120(Suppl 1):S4\u2013S5","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"1947_CR24","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/clind\/15.Supplement_1.S206","volume":"15","author":"WT Hughes","year":"1992","unstructured":"Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS (1992) Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Clin Infect Dis 15(Suppl 1):S206\u2013S215","journal-title":"Clin Infect Dis"},{"key":"1947_CR25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1128\/AAC.39.2.445","volume":"39","author":"A Cometta","year":"1995","unstructured":"Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP (1995) Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 39:445\u2013452","journal-title":"Antimicrob Agents Chemother"},{"key":"1947_CR26","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/clinids\/23.6.1234","volume":"23","author":"MB Edmond","year":"1996","unstructured":"Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP (1996) Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 23:1234\u20131239","journal-title":"Clin Infect Dis"},{"key":"1947_CR27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1086\/523588","volume":"46","author":"KM Erlandson","year":"2008","unstructured":"Erlandson KM, Sun J, Iwen PC, Rupp ME (2008) Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis 46:30\u201336","journal-title":"Clin Infect Dis"},{"key":"1947_CR28","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s00520-010-1038-z","volume":"19","author":"S Kraft","year":"2011","unstructured":"Kraft S, Mackler E, Schlickman P, Welch K, DePestel DD (2011) Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Support Care Cancer 19:1969\u20131974","journal-title":"Support Care Cancer"},{"key":"1947_CR29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/IPC.0b013e31822b7f6e","volume":"19","author":"LL Bio","year":"2011","unstructured":"Bio LL, Perez ME, MacDougall C, Gallagher JC (2011) Comparison of linezolid and daptomycin in the treatment of vancomycin-resistant enterococcal bacteremia. Inf Dis Clin Pract 19:343\u2013347","journal-title":"Inf Dis Clin Pract"},{"key":"1947_CR30","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1128\/AAC.00943-08","volume":"53","author":"JS Bubalo","year":"2009","unstructured":"Bubalo JS, Munar MY, Cherala G, Hayes-Lattin B, Maziarz R (2009) Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother 53:428\u2013434","journal-title":"Antimicrob Agents Chemother"},{"key":"1947_CR31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/AAC.01454-12","volume":"57","author":"TT Tran","year":"2013","unstructured":"Tran TT, Panesso D, Gao H, Roh JH, Munita JM, Reyes J, Diaz L, Lobos EA, Shamoo Y, Mishra NN, Bayer AS, Murray BE, Weinstock GM, Arias CA (2013) Whole-genome analysis of a daptomycin-susceptible Enterococcus faecium strain and its daptomycin-resistant variant arising during therapy. Antimicrob Agents Chemother 57:261\u201326832","journal-title":"Antimicrob Agents Chemother"},{"key":"1947_CR32","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ajic.2006.04.205","volume":"34","author":"MJ Matar","year":"2006","unstructured":"Matar MJ, Tarrand J, Raad I, Rolston KV (2006) Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. Am J Infect Control 34:534\u2013536","journal-title":"Am J Infect Control"},{"key":"1947_CR33","first-page":"815","volume":"6","author":"KV Rolston","year":"2008","unstructured":"Rolston KV (2008) Review: daptomycin for the treatment of gram-positive infections in neutropenic cancer patients. Clin Adv Hematol Oncol 6:815\u2013817","journal-title":"Clin Adv Hematol Oncol"},{"key":"1947_CR34","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.1128\/AAC.00168-11","volume":"55","author":"JA Bosso","year":"2011","unstructured":"Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, Mauldin PD (2011) The relationship between vancomycin through concentrations and nephrotoxicity: a prospective, multi-center trial. Antimicrob Agents Chemother 55:5475\u20135479","journal-title":"Antimicrob Agents Chemother"},{"key":"1947_CR35","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Lomaestro B, Graves J, Drusano GL (2008) Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52:1330\u20131336","journal-title":"Antimicrob Agents Chemother"},{"key":"1947_CR36","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1128\/AAC.00350-06","volume":"51","author":"I Raad","year":"2007","unstructured":"Raad I, Hanna H, Jiang Y, Dvorak T, Reitzel R, Chaiban G, Sherertz R, Hachem R (2007) Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 51:1656\u20131660","journal-title":"Antimicrob Agents Chemother"},{"key":"1947_CR37","unstructured":"ZYVOX\u00ae (linezolid) (2008) [package insert]. New York, NY: Pharmacia & Upjohn: Division of Pfizer, Inc"},{"key":"1947_CR38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1473-3099(07)70312-2","volume":"8","author":"ME Falagas","year":"2008","unstructured":"Falagas ME, Siempos II, Vardakas KZ (2008) Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 8:53\u201366","journal-title":"Lancet Infect Dis"},{"key":"1947_CR39","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1592\/phco.27.8.1189","volume":"27","author":"M Narita","year":"2007","unstructured":"Narita M, Tsuji BT, Yu VL (2007) Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 27:1189\u20131197","journal-title":"Pharmacotherapy"},{"key":"1947_CR40","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/jac\/dkq238","volume":"65","author":"VE Mulanovich","year":"2010","unstructured":"Mulanovich VE, Huband MD, McCurdy SP, Lemmon MM, Lescoe M, Jiang Y, Rolston KV, LaSala PR (2010) Emergence of linezolid-resistant coagulase-negative Staphylococcus in a cancer centre linked to increased linezolid utilization. J Antimicrob Chemother 65:2001\u20132004","journal-title":"J Antimicrob Chemother"},{"issue":"16","key":"1947_CR41","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038\u201351","journal-title":"J Clin Oncol"},{"key":"1947_CR42","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1086\/430352","volume":"191","author":"JA Silverman","year":"2005","unstructured":"Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J (2005) Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191:2149\u20132152","journal-title":"J Infect Dis"},{"key":"1947_CR43","first-page":"2222","volume-title":"Cancer medicine","author":"KVI Rolston","year":"2006","unstructured":"Rolston KVI, Bodey GP (2006) Infections in patients with cancer. In: Kufe DW, Frei EI, Holland JF et al (eds) Cancer medicine, 7th edn. BC Decker, Inc., Hamilton, Ontario, Canada, pp 2222\u20132245","edition":"7"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1947-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-013-1947-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1947-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T19:31:45Z","timestamp":1563737505000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-013-1947-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,24]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["1947"],"URL":"https:\/\/doi.org\/10.1007\/s00520-013-1947-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,24]]}}}